Project Grant R01HL183068
Award Date 9/15/26
Completion Date 5/31/31
Dollars Obligated $739K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $744,157 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of lung cell fate determination in the conducting airways and alveolar epithelium. The research investigates how SOX9+ progenitors produce SOX2+ cells to form conducting airways and generate AT1/2 cells to form alveoli, with emphasis on Hippo signaling and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1,231,094 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to decipher the molecular mechanism of pediatric interstitial lung disease caused by surfactant protein C (SFTPC) gene mutations and advance targeted therapies. The University of Pennsylvania research team, led by Dr. Jeremy Katzen, will develop and leverage in vivo mouse models and human induced...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...
- The National Heart, Lung, and Blood Institute awarded the University of Pennsylvania $157,658 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, K99HL185935) to elucidate mechanical regulation of the lung gas exchange interface through investigation of how capillary endothelial cells and alveolar epithelial cells respond to biophysical strain during breathing. The award funds research into mechanically induced capillary endothelial cells (MICAPs) identified in...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,895 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of biological sex and the innate immune response in neonatal bronchopulmonary dysplasia. The award funds research examining how sex chromosomes and X-chromosome inactivation regulate neonatal lung macrophage polarization in response to hyperoxic injury. The project will establish the...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...